Femara helps prevent the return of breast cancer
Key points
- In more good news for women suffering from breast cancer a study by the the Swiss drugmaker Novartis has shown that their drug Femara benefits women with hormone-sensitive early breast cancer.
- The drug company says that postmenopausal women who switched from a placebo to Femara experienced a 69-percent reduction in the risk of their breast cancer returning.
- The new data has been presented at the 28th annual San Antonio Breast Cancer Symposium in Texas and is the first time that an aromatase inhibitor has shown a benefit in starting therapy up to five years after the end of standard Tamoxifen treatment.
In more good news for women suffering from breast cancer a study by the the Swiss drugmaker Novartis has shown that their drug Femara benefits women with hormone-sensitive early breast cancer.
The drug company says that postmenopausal women who switched from a placebo to Femara experienced a 69-percent reduction in the risk of their breast cancer returning.
The new data has been presented at the 28th annual San Antonio Breast Cancer Symposium in Texas and is the first time that an aromatase inhibitor has shown a benefit in starting therapy up to five years after the end of standard Tamoxifen treatment.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsChemoprevention biomarker for breast cancer identified
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer…
10 November 2010
NewsAsthma drug prevents spread of breast cancer: study
A drug commonly used in Japan and Korea to treat asthma has been found to stop the spread of breast cancer cells traditionally resistant to chemotherapy, according to a new study led by St. Michael's pathologist Dr.…
4 November 2010
NewsRemoving 2mm around breast cancer tumors prevents residual disease in 98 percent of patients
Removing an extra two millimetres around an area of invasive breast cancer is sufficient to minimise any residual disease in 98 per cent of patients, according to research published in the November issue of IJCP, the…
